Stock AnalizMerck & Co., Inc. MRK
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Merck & Co., Inc. (MRK) is a healthcare company listed in the US with a market value of about $364.3B. In the twelve months to September 30, 2026 it had revenue of $67.4B and net income of $2.5B, a net margin of 3.6%.
Its overall Stock Analiz score is 2.8 out of 5 (average). The strongest part is track record (5/5); the weakest is value (0/5).
Key numbers: a P/E of 150.8, a price to free cash flow of 24.7, 5-year revenue growth of 9% a year, a 5-year average ROIC of 16%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 31% below the current price.
Score: 2.8 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- ROE above 15%
- Positive free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $67.4B | $65.0B | $64.2B | $60.1B | $59.3B | $48.7B | $41.5B | $39.1B | $42.3B | $40.1B | $39.8B |
| Net income | $2.5B | $18.3B | $17.1B | $365M | $14.5B | $13.0B | $7.1B | $9.8B | $6.2B | $2.4B | $3.9B |
| Free cash flow | $14.7B | $12.4B | $18.1B | $9.1B | $14.7B | $8.7B | $5.8B | $10.1B | $8.3B | $4.6B | $8.8B |
| EPS (diluted) | $0.98 | $7.28 | $6.74 | $0.14 | $5.71 | $5.14 | $2.78 | $3.81 | $2.32 | $0.87 | $1.41 |
| Net margin | 3.6% | 28.1% | 26.7% | 0.6% | 24.5% | 26.8% | 17.0% | 25.2% | 14.7% | 6.0% | 9.8% |
| ROIC | — | 18.9% | 21.6% | 3.2% | 19.7% | 18.0% | 8.8% | 11.8% | 13.0% | 9.8% | 7.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 26 analysts is $161.53, 9% above the current price; targets range from $105.00 to $186.00; the consensus rating is “Buy”; expected EPS is $2.78 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Merck & Co.’s P/E ratio?
About 150.8, based on the last twelve months of diluted earnings per share (forward P/E about 17.6).
Is Merck & Co. stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 31% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Merck & Co. pay a dividend?
Yes. The dividend yield is about 2.31%, and it has paid dividends for 10 years in our data.
Is Merck & Co. a good stock to buy?
We do not give buy or sell advice. Merck & Co. scores 2.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.